60 years of metformin use: a glance at the past and a look to the future

[1]  F. T. E. Group,et al.  Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study , 2017, Diabetologia.

[2]  C. Bailey,et al.  Metformin: historical overview , 2017, Diabetologia.

[3]  D. Hardie,et al.  The mechanisms of action of metformin , 2017, Diabetologia.

[4]  J. Florez.  The pharmacogenetics of metformin , 2017, Diabetologia.

[5]  L. Ford,et al.  Repurposing metformin for the prevention of cancer and cancer recurrence , 2017, Diabetologia.

[6]  D. Ehrmann,et al.  Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome , 2017, Diabetologia.

[7]  S. Griffin,et al.  Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes , 2017, Diabetologia.

[8]  L. Tamariz,et al.  Metformin and ageing: improving ageing outcomes beyond glycaemic control , 2017, Diabetologia.

[9]  J. Petrie,et al.  A new perspective on metformin therapy in type 1 diabetes , 2017, Diabetologia.

[10]  M. Loeken,et al.  Metformin use in pregnancy: promises and uncertainties , 2017, Diabetologia.

[11]  S. Inzucchi,et al.  Metformin: clinical use in type 2 diabetes , 2017, Diabetologia.

[12]  M. Pollak.  The effects of metformin on gut microbiota and the immune system as research frontiers , 2017, Diabetologia.

[13]  L. Donnelly,et al.  Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study , 2017, Diabetes, obesity & metabolism.

[14]  K. Bhaskaran,et al.  Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation , 2016, International journal of epidemiology.

[15]  K. Bhaskaran,et al.  Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation , 2016, International journal of epidemiology.

[16]  J. Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[17]  R. DeFronzo,et al.  Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm , 2016, Diabetes Care.

[18]  Mark I. McCarthy,et al.  Variation in the Glucose Transporter gene SLC2A2 is associated with glycaemic response to metformin , 2016, Nature Genetics.

[19]  A. Tsapas,et al.  Empagliflozin , Cardiovascular Outcomes , and Mortality in Type 2 Diabetes , 2015 .

[20]  C. Bailey,et al.  Metformin and the gastrointestinal tract , 2016, Diabetologia.

[21]  I. Petersen,et al.  Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study , 2016, BMJ Open.

[22]  V. Montori,et al.  Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. , 2015, The Journal of clinical endocrinology and metabolism.

[23]  Silvio E. Inzucchi,et al.  Metformin in patients with type 2 diabetes and kidney disease: a systematic review. , 2014, JAMA.

[24]  V. Anisimov.  Metformin: Do we finally have an anti-aging drug? , 2013, Cell cycle.

[25]  A. Farmer,et al.  Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials , 2012, Diabetologia.

[26]  E. Salpeter,et al.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. , 2010, The Cochrane database of systematic reviews.

[27]  R. DeFronzo,et al.  Relationship of baseline HbA1c and efficacy of current glucose‐lowering therapies: a meta‐analysis of randomized clinical trials , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[28]  S. Majumdar,et al.  Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin , 2006, Diabetes Care.

[29]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[30]  H. Parving,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[31]  M J Ball,et al.  Healthcare Informatics , 2009, Encyclopedia of Database Systems.

[32]  F. Ovalle.  10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes , 2009 .